Literature DB >> 20087448

Hypertrophic cardiomyopathy family with double-heterozygous mutations; does disease severity suggest doubleheterozygosity?

I A W van Rijsingen1, J F Hermans-van Ast, Y H J M Arens, S M Schalla, C E M de Die-Smulders, A van den Wijngaard, Y M Pinto.   

Abstract

Background. With the improvement in genetic testing over time, double-heterozygous mutations are more often found by coincidence in families with hypertrophic cardiomyopathy (HCM). Double heterozygosity can be a cause of the wellknown clinical diversity within HCM families.Methods and results. We describe a family in which members carry either a single mutation or are double heterozygous for mutations in myosin heavy chain gene (MYH7) and cysteine and glycine-rich protein 3 (CSRP3). The described family emphasises the idea of a more severe clinical phenotype with double-heterozygous mutations. It also highlights the importance of cardiological screening where NT-proBNP may serve as an added diagnostic tool.Conclusion. With a more severe inexplicable phenotype of HCM within a family, one should consider the possibility of double-heterozygous mutations. This implies that in such families, even when one disease-causing mutation is found, all the family members still have an implication for cardiological screening parallel to extended genetic screening. (Neth Heart J 2009;17:458-63.).

Entities:  

Keywords:  cardiomyopathy; double-heterozygous mutations; genetics; hypertrophic; proBNP

Year:  2009        PMID: 20087448      PMCID: PMC2804077          DOI: 10.1007/BF03086304

Source DB:  PubMed          Journal:  Neth Heart J        ISSN: 1568-5888            Impact factor:   2.380


  32 in total

1.  Compound and double mutations in patients with hypertrophic cardiomyopathy: implications for genetic testing and counselling.

Authors:  J Ingles; A Doolan; C Chiu; J Seidman; C Seidman; C Semsarian
Journal:  J Med Genet       Date:  2005-10       Impact factor: 6.318

Review 2.  A contemporary approach to hypertrophic cardiomyopathy.

Authors:  Carolyn Y Ho; Christine E Seidman
Journal:  Circulation       Date:  2006-06-20       Impact factor: 29.690

Review 3.  Molecular genetics of hypertrophic cardiomyopathy.

Authors:  J A Towbin
Journal:  Curr Cardiol Rep       Date:  2000-03       Impact factor: 2.931

4.  Genotype-phenotype relationships involving hypertrophic cardiomyopathy-associated mutations in titin, muscle LIM protein, and telethonin.

Authors:  J Martijn Bos; Rainer N Poley; Melissa Ny; David J Tester; Xiaolei Xu; Matteo Vatta; Jeffrey A Towbin; Bernard J Gersh; Steve R Ommen; Michael J Ackerman
Journal:  Mol Genet Metab       Date:  2005-12-13       Impact factor: 4.797

5.  Mutations in the human muscle LIM protein gene in families with hypertrophic cardiomyopathy.

Authors:  Christian Geier; Andreas Perrot; Cemil Ozcelik; Priska Binner; Damian Counsell; Katrin Hoffmann; Bernhard Pilz; Yvonne Martiniak; Katja Gehmlich; Peter F M van der Ven; Dieter O Fürst; Arnold Vornwald; Eberhard von Hodenberg; Peter Nürnberg; Thomas Scheffold; Rainer Dietz; Karl Josef Osterziel
Journal:  Circulation       Date:  2003-03-18       Impact factor: 29.690

6.  Prevalence of hypertrophic cardiomyopathy in a general population of young adults. Echocardiographic analysis of 4111 subjects in the CARDIA Study. Coronary Artery Risk Development in (Young) Adults.

Authors:  B J Maron; J M Gardin; J M Flack; S S Gidding; T T Kurosaki; D E Bild
Journal:  Circulation       Date:  1995-08-15       Impact factor: 29.690

Review 7.  Impact of multiple gene mutations in determining the severity of cardiomyopathy and heart failure.

Authors:  Tatiana Tsoutsman; Richard D Bagnall; Christopher Semsarian
Journal:  Clin Exp Pharmacol Physiol       Date:  2008-08-29       Impact factor: 2.557

8.  Severe heart failure and early mortality in a double-mutation mouse model of familial hypertrophic cardiomyopathy.

Authors:  Tatiana Tsoutsman; Matthew Kelly; Dominic C H Ng; Ju-En Tan; Emily Tu; Lien Lam; Marie A Bogoyevitch; Christine E Seidman; J G Seidman; Christopher Semsarian
Journal:  Circulation       Date:  2008-03-24       Impact factor: 29.690

9.  Relationship between sex, shape, and substrate in hypertrophic cardiomyopathy.

Authors:  J Martijn Bos; Jeanne L Theis; A Jamil Tajik; Bernard J Gersh; Steve R Ommen; Michael J Ackerman
Journal:  Am Heart J       Date:  2008-02-21       Impact factor: 4.749

10.  Significance of plasma levels of N-terminal Pro-B-type natriuretic peptide on left ventricular remodeling in non-obstructive hypertrophic cardiomyopathy attributable to the Asp175Asn mutation in the alpha-tropomyosin gene.

Authors:  Jarkko Magga; Petri Sipola; Olli Vuolteenaho; Juha Risteli; Pertti Jääskeläinen; Keijo Peuhkurinen; Johanna Kuusisto
Journal:  Am J Cardiol       Date:  2008-02-20       Impact factor: 2.778

View more
  6 in total

1.  Evaluation of hypertrophic cardiomyopathy: new horizons for CMR?

Authors:  E E van der Wall; H M Siebelink; J J Bax
Journal:  Neth Heart J       Date:  2010-03       Impact factor: 2.380

2.  Cardiomyopathies: a revolution in molecular medicine and cardiac imaging.

Authors:  F J Ten Cate
Journal:  Neth Heart J       Date:  2009-12       Impact factor: 2.380

3.  Accurate zygote-specific discrimination of single-nucleotide polymorphisms using microfluidic electrochemical DNA melting curves.

Authors:  Allen H J Yang; Kuangwen Hsieh; Adriana S Patterson; B Scott Ferguson; Michael Eisenstein; Kevin W Plaxco; H Tom Soh
Journal:  Angew Chem Int Ed Engl       Date:  2014-02-12       Impact factor: 15.336

4.  Left ventricular mass assessment by CMR; how to define the optimal index.

Authors:  E E van der Wall; H M Siebelink; J J Bax
Journal:  Int J Cardiovasc Imaging       Date:  2010-03-06       Impact factor: 2.357

Review 5.  Genetic advances in sarcomeric cardiomyopathies: state of the art.

Authors:  Carolyn Y Ho; Philippe Charron; Pascale Richard; Francesca Girolami; Karin Y Van Spaendonck-Zwarts; Yigal Pinto
Journal:  Cardiovasc Res       Date:  2015-01-29       Impact factor: 10.787

6.  Identification of fibrillin 1 gene mutations in patients with bicuspid aortic valve (BAV) without Marfan syndrome.

Authors:  Guglielmina Pepe; Stefano Nistri; Betti Giusti; Elena Sticchi; Monica Attanasio; Cristina Porciani; Rosanna Abbate; Robert O Bonow; Magdi Yacoub; Gian Franco Gensini
Journal:  BMC Med Genet       Date:  2014-02-24       Impact factor: 2.103

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.